Clinical Trials

Clinical Trials

Below is a list of currently enrolling Clinical Trials at the Appalachian Clinical and Translational Science Institute (ACTSI). If you would like additional information about a specific trial, you can call the contact number provided and speak with a study coordinator.

Additional information about each trial can be obtained at ClinicalTrials.gov by clicking on the descriptions below

Study ID PI Description Contact Information
NCT02329327 Cornell "A Study in Patients with Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Revers the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (ANNEXA-4)" Robin Ashford: 304-691-1082
NCT01442194 Ferguson "Long-term, Prosepctive, Multi- national, parallel-cohort study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease- Modifying Therapy" CLR1104 Linda Morgan: 304-691-1213
NCT02239120 Nolte "Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)" Melissa Marcum: 304-691-8560

Rebecca Smith: 304-691-1834
NCT02477618 Shah "A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of SAGE547 Injection in the Treatment of Subjects with Super Refrac-tory Status Epilepticus" Robin Ashford: 304-691-1082

Doug Melton: 304-691-8618
NCT01797185 Ferguson "Open-label, safety study of SPARC1104 in Subjects with Spasticity due to MS" Linda Morgan: 304-691-1213
NCT02373904 Cheung "A Prospective, Multi-Center Study of the IlluminOSS Photodynamic Bone Sta-bilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus from Metastatic Bone Disease" Linda Morgan: 304-691-1213
NCT03114657 Neitch "A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients with Prodromal to Mild Alzheimer's Disease" Melissa Marcum: 304-691-8560
NCT02792218 Ferguson "A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Comparing the Efficacy and Safety of Ofatumumab versus Teriflunomide in Patients with Relapsing Multiple Sclerosis" Linda Morgan: 304-691-1213

Doug Melton: 304-691-8618
NCT02878330 Lambros "A Phase 2B Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Mono-clonal Antibody with an Extended Half-Life Against Respiratory Synctial Virus, in Healthy Preterm Infants" Robin Ashford: 304-691-1082